Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report specifically addresses corporate governance updates regarding directorate changes effective April 1, 2011.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding personnel appointments and does not contain financial performance data.
Material Changes
The primary material change disclosed is the appointment of two new Non-Executive Directors:
- Ms. Judy Lewent: Appointed effective April 1, 2011.
- Ms. Stacey Cartwright: Appointed effective April 1, 2011.
The company confirmed there are no further disclosures required under Listing Rule 9.6.13R regarding these appointments.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Ms. Judy Lewent holds 121 Ordinary Shares of GlaxoSmithKline plc.
- Ms. Stacey Cartwright holds 121 Ordinary Shares of GlaxoSmithKline plc.
- The appointments of both directors became effective on April 1, 2011.
- The report was signed by Victoria Whyte, Company Secretary, on March 11, 2011.